Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Actively Recruiting
Led by Children's Oncology Group · Updated on 2026-08-25
5951
Participants Needed
231
Research Sites
N/A
Total Duration
Researchers are evaluating whether adding inotuzumab ozogamicin to post-induction chemotherapy and immunotherapy improves outcomes for children and young adults with High-Risk B-cell Acute Lymphoblastic Leukemia B-ALL. This phase III trial also studies patients with mixed phenotype acute leukemia MPAL and B-lymphoblastic lymphoma B-LLy treated with standard acute lymphoblastic leukemia therapy. The study aims to understand if this addition maintains or improves five-year event-free survival and assesses side effects, quality of life, treatment adherence, immune impact, and social factors affecting outcomes. Participants first receive induction therapy with a combination of chemotherapy drugs including vincristine, daunorubicin, methotrexate, and steroids, among others. After induction, patients with high-risk B-ALL and CD22 positive status are randomized into two groups one receiving standard chemo-immunotherapy including blinatumomab Arm D, and the other receiving modified chemo-immunotherapy with inotuzumab ozogamicin replacing parts of consolidation and delayed intensification Arm E. Patients with MPAL and B-LLy receive tailored chemotherapy regimens without inotuzumab. Treatment phases include consolidation, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance therapy over up to two years. Throughout the study, participants undergo blood sample collection, bone marrow aspiration and biopsy, and imaging studies such as CT, MRI, PET, and bone scans as appropriate. Researchers monitor treatment effects, adverse events, and quality of life using patient-reported outcomes. After completing treatment, participants are followed for up to five years with regular visits to assess disease status, survival, and long-term effects.
CONDITIONS
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Children's Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Inotuzumab ozogamicin + chemotherapy | Chemotherapy backbone only | Guideline standard chemotherapy |
|---|---|---|---|
| What it is | Inotuzumab ozogamicin, a CD22‑targeted antibody‑drug conjugate, added to the same chemotherapy backbone | Standard mBFM‑based post‑induction chemotherapy backbone | Current guideline‑recommended post‑induction chemotherapy alone per NCCN Pediatric ALL guidelines |
| Primary use | Being evaluated as addition to chemotherapy to potentially improve event‑free survival | Serves as the comparator arm receiving standard chemotherapy only | Represents current standard post‑induction treatment without inotuzumab |
| How it is given or performed | Inotuzumab ozogamicin given intravenously alongside mBFM chemotherapy | Chemotherapy per mBFM protocol post‑induction | Chemotherapy alone as per guideline‑recommended protocols |
| Evidence status | Efficacy under investigation; study aims to assess improvement in 5‑year event‑free survival | Longstanding evidence supports efficacy of mBFM chemotherapy backbone in high‑risk pediatric ALL | Chemotherapy alone demonstrated benefit in guideline recommendations |
| Important risks | Potential risk of sinusoidal obstruction syndrome and hepatotoxicity when adding inotuzumab ozogamicin | Known chemotherapy‑related toxicities per mBFM regimen | Toxicities aligned with chemotherapy backbone only |
| Important limitations | Long‑term safety and efficacy unknown; not yet standard of care for newly diagnosed post‑induction high‑risk cases | May be insufficient for MRD‑positive or very high‑risk disease subsets | Does not include targeted agents like inotuzumab ozogamicin that may benefit MRD‑positive high‑risk patients |
| Patient‑relevant outcome | Potential to improve 5‑year event‑free survival, under evaluation | Established long‑term outcomes in high‑risk pediatric ALL | Current outcomes based on chemotherapy alone |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 5 weeks
Participants receive initial chemotherapy including drugs like vincristine, daunorubicin, methotrexate, and steroids over 5 weeks to reduce leukemia cells.
Multiple visits for drug administration and monitoring
Duration - Up to 2 years
Participants with high-risk B-ALL and CD22 positivity are randomized to receive either standard chemo-immunotherapy or modified therapy including inotuzumab ozogamicin. Patients with MPAL or B-LLy receive tailored chemotherapy.
Regular visits for treatment cycles and monitoring
Duration - Up to 5 years
After treatment, participants are monitored with regular visits to assess disease status, survival, and long-term effects for up to five years.
Visits every 3 months for 2 years, then less frequently
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Children's Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor